down arrow

Vascular Biogenics Ltd.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IL0011327454
USD
0.00
0.00 (0.00%)

Jun 30

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.000.67
Valuation
Technical
Day's Volume

CASH

1

Shareholding (Jun 2024)

FII

5.97%

Held by 44 FIIs

DII

90.7%

Held by 0 DIIs

Promoter

3.33%

How big is Vascular Biogenics Ltd.?

22-Jun-2025

As of Jun 17, Vascular Biogenics Ltd. has a market capitalization of 0.00, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -12.50 million over the latest four quarters. Shareholder's funds are 22.45 million, and total assets are 29.66 million as of Dec 22.

Market Cap: As of Jun 17, Vascular Biogenics Ltd. has a market capitalization of 0.00, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the sum of Net Sales is 0.00 Million, and the sum of Net Profit is -12.50 Million.<BR><BR>Balance Sheet Snapshot: As of Dec 22, the Shareholder's Funds amount to 22.45 Million, and the Total Assets are 29.66 Million.

Read More

Who are in the management team of Vascular Biogenics Ltd.?

22-Jun-2025

As of March 2022, the management team of Vascular Biogenics Ltd. includes Dr. Bennett Shapiro (Non-Executive Independent Chairman), Prof. Dror Harats (CEO), and several Non-Executive Independent Directors: Ms. Ruth Alon, Prof. Ruth Arnon, Dr. Shmuel Ben Zvi, and Dr. Ron Cohen. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Vascular Biogenics Ltd. includes the following individuals:<BR><BR>- Dr. Bennett Shapiro, Non-Executive Independent Chairman of the Board<BR>- Prof. Dror Harats, Chief Executive Officer and Director<BR>- Ms. Ruth Alon, Non-Executive Independent Director<BR>- Prof. Ruth Arnon, Non-Executive Independent Director<BR>- Dr. Shmuel Ben Zvi, Non-Executive Independent Director<BR>- Dr. Ron Cohen, Non-Executive Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More

Is Vascular Biogenics Ltd. overvalued or undervalued?

20-Sep-2025

As of March 28, 2019, Vascular Biogenics Ltd. is considered a poor investment due to its severe financial distress, indicated by a negative P/E ratio, low EV to EBITDA, and a year-to-date decline of 99.64%, making it overvalued compared to its peers.

As of 28 March 2019, the valuation grade for Vascular Biogenics Ltd. moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company appears to be overvalued given its current financial metrics, including a P/E ratio of -0.0001 and an EV to EBITDA of 0.28, which are both indicative of severe financial distress. Additionally, the negative ROE of -170.61% further underscores the challenges the company faces.<BR><BR>In comparison to its peers, Vascular Biogenics Ltd. has a significantly lower P/E ratio than Equillium, Inc. at -5.5396 and OncoCyte Corp. at -2.9218, both of which are also categorized as risky. The company's returns have been dismal, with a year-to-date decline of -99.64% compared to a 12.22% gain in the S&P 500, reinforcing the notion that it is not a viable investment at this time.

Read More

Is Vascular Biogenics Ltd. technically bullish or bearish?

20-Sep-2025

As of December 16, 2024, Vascular Biogenics Ltd. shows a mildly bearish technical trend with mixed signals across indicators, significantly underperforming the S&P 500 with year-to-date returns of -99.64% compared to its 12.22%.

As of 16 December 2024, the technical trend for Vascular Biogenics Ltd. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD also shows mild bullishness. However, the daily moving averages are mildly bearish, and the KST is bearish on both weekly and monthly time frames. The Bollinger Bands are sideways weekly but mildly bearish monthly, and there is no trend indicated by Dow Theory or OBV.<BR><BR>The company has significantly underperformed compared to the S&P 500, with a year-to-date return of -99.64% versus the S&P 500's 12.22%, and a one-year return of -99.98% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven by mixed signals across various indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million (Micro Cap)

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.49

stock-summary
Return on Equity

-170.61%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2024)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
-99.75%
0%
-99.75%
1 Year
-99.98%
0%
-99.98%
2 Years
-100.0%
0%
-100.0%
3 Years
-100.0%
0%
-100.0%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

Vascular Biogenics Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Vascular Biogenics Ltd. technically bullish or bearish?

As of 16 December 2024, the technical trend for Vascular Biogenics Ltd. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD also shows mild bullishness. However, the daily moving averages are mildly bearish, and the KST is bearish on both weekly and monthly time frames. The Bollinger Bands are sideways weekly but mildly bearish monthly, and there is no trend indicated by Dow Theory or OBV. The company has significantly underperformed compared to the S&P 500, with a year-to-date return of -99.64% versus the S&P 500's 12.22%, and a one-year return of -99.98% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven by mixed signals across various indicators....

Read More

Is Vascular Biogenics Ltd. overvalued or undervalued?

As of 28 March 2019, the valuation grade for Vascular Biogenics Ltd. moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company appears to be overvalued given its current financial metrics, including a P/E ratio of -0.0001 and an EV to EBITDA of 0.28, which are both indicative of severe financial distress. Additionally, the negative ROE of -170.61% further underscores the challenges the company faces. In comparison to its peers, Vascular Biogenics Ltd. has a significantly lower P/E ratio than Equillium, Inc. at -5.5396 and OncoCyte Corp. at -2.9218, both of which are also categorized as risky. The company's returns have been dismal, with a year-to-date decline of -99.64% compared to a 12.22% gain in the S&P 500, reinforcing the notion that it is not a viable investment at this time....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-3.82%
EBIT to Interest (avg)
-25.30
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.49
Sales to Capital Employed (avg)
0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
5.98%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
0.00
EV to EBIT
0.28
EV to EBITDA
0.28
EV to Capital Employed
-0.97
EV to Sales
-3.54
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-170.61%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 44 Foreign Institutions (5.97%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2024 is 0.00% vs -100.00% in Jun 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2024 is -477.78% vs 90.43% in Jun 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.30",
          "val2": "-0.30",
          "chgp": "-1,666.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "-0.30",
          "chgp": "133.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.20",
          "val2": "-0.90",
          "chgp": "-477.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,690,000.00%",
          "val2": "0.00%",
          "chgp": "-2,69,000.00%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is -12.50% vs -11.11% in Dec 2021",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is -8.03% vs -23.55% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.70",
          "val2": "0.80",
          "chgp": "-12.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-31.80",
          "val2": "-28.70",
          "chgp": "-10.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-32.30",
          "val2": "-29.90",
          "chgp": "-8.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-49,928.60%",
          "val2": "-39,057.30%",
          "chgp": "-1,087.13%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'24 - YoYstock-summary
Jun'24
Jun'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-5.30
-0.30
-1,666.67%
Interest
0.00
0.00
Exceptional Items
0.10
-0.30
133.33%
Consolidate Net Profit
-5.20
-0.90
-477.78%
Operating Profit Margin (Excl OI)
-2,690,000.00%
0.00%
-2,69,000.00%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2024 is 0.00% vs -100.00% in Jun 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2024 is -477.78% vs 90.43% in Jun 2023

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
0.70
0.80
-12.50%
Operating Profit (PBDIT) excl Other Income
-31.80
-28.70
-10.80%
Interest
0.10
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-32.30
-29.90
-8.03%
Operating Profit Margin (Excl OI)
-49,928.60%
-39,057.30%
-1,087.13%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2022 is -12.50% vs -11.11% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is -8.03% vs -23.55% in Dec 2021

All Annual Resultsstock-summary
stock-summaryCompany CV
About Vascular Biogenics Ltd. stock-summary
stock-summary
Vascular Biogenics Ltd.
Pharmaceuticals & Biotechnology
Vascular Biogenics Ltd. is Israel- based late-stage clinical biopharmaceutical company, focused on the discovery, development and commercialization of treatments for cancer. VBL’s clinical pipeline is based on two distinct platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. The Company has developed two programs based on these platforms an oncology program and an anti-inflammatory program. The Company’s lead oncology product VB-111, is a targeted anti-cancer gene-therapy agent that is positioned to potentially treat a wide range of solid tumors. VBL has also developed platform of investigational orally-available small molecules, designated Lecinoxoids, for the treatment of chronic immune-related indications.
Company Coordinates stock-summary
Company Details
8 HaSatat St. , MODIIN None : 7178106
stock-summary
Tel: 972 8 9935000
stock-summary
http://www.vblrx.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."